[Role of radiotherapy in the management of node-positive prostate cancer]

S Supiot; M Doré; E Rio; P Cellier; N Mesguez-Nebout; A Goineau

doi:10.1016/j.canrad.2016.06.002

[Role of radiotherapy in the management of node-positive prostate cancer]

Cancer Radiother. 2016 Oct;20(6-7):442-4. doi: 10.1016/j.canrad.2016.06.002. Epub 2016 Aug 27.

[Article in French]

Authors

S Supiot¹, M Doré², E Rio², P Cellier², N Mesguez-Nebout², A Goineau²

Affiliations

¹ Département de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France. Electronic address: [email protected].
² Département de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.

PMID: 27575537
DOI: 10.1016/j.canrad.2016.06.002

Abstract

Node-positive prostate cancer patients represent a small proportion of all prostate cancers for whom limited prospective information is available. Most retrospective or cohort data strongly suggest however that radiotherapy combined with androgen-depriving therapies is the preferable treatment in this setting. Only randomized clinical trials would be able to better define both radiotherapy (dose? volume? fractionation?) and androgen-depriving therapies (duration? role of novel androgen-depriving therapy?) modalities.

Keywords: Adénome de la prostate; Androgen depriving therapy; Cancer de la prostate métastatique; Hormonetherapy; Hormonothérapie; Irradiation; Metastatic prostate cancer; N1; Oligometastases; Oligométastases; Pelvis; Prostate adenocarcinoma; cN1; pN1.

Publication types

Review

MeSH terms

Androgen Antagonists / therapeutic use*
Humans
Lymphatic Metastasis*
Male
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology
Prostatic Neoplasms / radiotherapy*
Radiotherapy, Adjuvant

Substances

Androgen Antagonists